Study of AZD1222 for the Prevention of COVID-19 in Japan

For subjects in part 1 will have that route of Administration as Intramuscular, 5 × 1010 vp (nominal, ± 1.5 × 1010 vp) on V2

For subjects in placebo will have that route of Administration as Intramuscular 0.9% (w/v) saline on V2 and V6.